organization · Reporting owner
Merck & Co., Inc.
Disclosed activity across 10 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARQULE INCARQL · Entity 11927 | 10% owner | December 06, 2019 | December 16, 2019 |
| BeOne Medicines Ltd.BGNE · Entity 2168 | 10% owner | February 08, 2016 | February 10, 2016 |
| NGM BIOPHARMACEUTICALS INCNGM · Entity 11997 | 10% owner | April 08, 2019 | April 09, 2019 |
| Pandion Therapeutics, Inc.PAND · Entity 11788 | 10% owner | February 24, 2021 | March 04, 2021 |
| Personalis, Inc.PSNL · Entity 4572 | 10% owner | December 19, 2024 | December 23, 2024 |
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | 10% owner | October 01, 2018 | October 02, 2018 |
| Yarrow Bioscience, Inc.MNLO · Entity 6871 | 10% owner | January 24, 2018 | January 25, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARQULE INC
Report date December 06, 2019 · Filed December 16, 2019
Jointly reported with Merck Sharp & Dohme Corp.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01SEC Table I · non-derivative | IndirectSee Footnotes | 0 |
Reported balance
Holding disclosure · report date 2019-12-06 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 F1: This Form 3 is being filed solely due to the entry by Merck Sharp & Dohme Corp. ("Parent") and Argon Merger Sub, Inc. ("Purchaser") into Support Agreements (each, a "Support Agreement") with certain stockholders of ArQule, Inc. ("ArQule"). The Support Agreements were entered into in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 6, 2019, by and among the Parent, Purchaser and ArQule. For additional information regarding the Support Agreements and the Merger Agreement, see the Schedule 13D filed by the Reporting Person with the Securities and Exchange Commission on December 16, 2019 (the "Schedule 13D"). F2: Purchaser is a direct wholly-owned subsidiary of Parent and Parent is a direct wholly-owned subsidiary of Merck & Co., Inc. ("Merck", and together with Parent, the "Reporting Persons"). As a result of certain provisions contained in the Support Agreements, the Reporting Persons may be deemed to have beneficial ownership of the shares of common stock covered by the Support Agreements and beneficially owned by the stockholders party thereto (an aggregate of 17,481,903 shares, which represent approximately 12.6% of ArQule's total outstanding shares as of the close of business on December 5, 2019, based on the representations made by ArQule in the Merger Agreement) for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")). F3: Each of the Reporting Persons declare that the filing of this Form 3 shall not be construed as an admission that the Reporting Persons are the beneficial owners of any securities reported in this Form 3. F4: Generally, upon the exercise of any security convertible or exchangeable for any ArQule common stock by the stockholders party to the Support Agreements, such shares of common stock acquired upon exercise thereof shall be subject to the Support Agreements and the Reporting Persons may be deemed to have beneficial ownership of such additional shares of common stock, if any. The Reporting Persons expressly disclaim any beneficial ownership of the securities reported herein, and the Reporting Persons do not have any pecuniary interest (as defined in Rule 16a-1(a)(2) of the Exchange Act) in any of the shares subject to the Support Agreements. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security | IndirectSee Footnotes | Not disclosed |
Reported balance
Holding disclosure · report date 2019-12-06 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: This Form 3 is being filed solely due to the entry by Merck Sharp & Dohme Corp. ("Parent") and Argon Merger Sub, Inc. ("Purchaser") into Support Agreements (each, a "Support Agreement") with certain stockholders of ArQule, Inc. ("ArQule"). The Support Agreements were entered into in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 6, 2019, by and among the Parent, Purchaser and ArQule. For additional information regarding the Support Agreements and the Merger Agreement, see the Schedule 13D filed by the Reporting Person with the Securities and Exchange Commission on December 16, 2019 (the "Schedule 13D"). F2: Purchaser is a direct wholly-owned subsidiary of Parent and Parent is a direct wholly-owned subsidiary of Merck & Co., Inc. ("Merck", and together with Parent, the "Reporting Persons"). As a result of certain provisions contained in the Support Agreements, the Reporting Persons may be deemed to have beneficial ownership of the shares of common stock covered by the Support Agreements and beneficially owned by the stockholders party thereto (an aggregate of 17,481,903 shares, which represent approximately 12.6% of ArQule's total outstanding shares as of the close of business on December 5, 2019, based on the representations made by ArQule in the Merger Agreement) for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")). F3: Each of the Reporting Persons declare that the filing of this Form 3 shall not be construed as an admission that the Reporting Persons are the beneficial owners of any securities reported in this Form 3. F4: Generally, upon the exercise of any security convertible or exchangeable for any ArQule common stock by the stockholders party to the Support Agreements, such shares of common stock acquired upon exercise thereof shall be subject to the Support Agreements and the Reporting Persons may be deemed to have beneficial ownership of such additional shares of common stock, if any. The Reporting Persons expressly disclaim any beneficial ownership of the securities reported herein, and the Reporting Persons do not have any pecuniary interest (as defined in Rule 16a-1(a)(2) of the Exchange Act) in any of the shares subject to the Support Agreements. |
| Common Stock Warrants (right to buy)SEC Table II · derivative / convertible security | IndirectSee Footnotes | Not disclosed |
Reported balance
Holding disclosure · report date 2019-12-06 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: This Form 3 is being filed solely due to the entry by Merck Sharp & Dohme Corp. ("Parent") and Argon Merger Sub, Inc. ("Purchaser") into Support Agreements (each, a "Support Agreement") with certain stockholders of ArQule, Inc. ("ArQule"). The Support Agreements were entered into in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 6, 2019, by and among the Parent, Purchaser and ArQule. For additional information regarding the Support Agreements and the Merger Agreement, see the Schedule 13D filed by the Reporting Person with the Securities and Exchange Commission on December 16, 2019 (the "Schedule 13D"). F2: Purchaser is a direct wholly-owned subsidiary of Parent and Parent is a direct wholly-owned subsidiary of Merck & Co., Inc. ("Merck", and together with Parent, the "Reporting Persons"). As a result of certain provisions contained in the Support Agreements, the Reporting Persons may be deemed to have beneficial ownership of the shares of common stock covered by the Support Agreements and beneficially owned by the stockholders party thereto (an aggregate of 17,481,903 shares, which represent approximately 12.6% of ArQule's total outstanding shares as of the close of business on December 5, 2019, based on the representations made by ArQule in the Merger Agreement) for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")). F3: Each of the Reporting Persons declare that the filing of this Form 3 shall not be construed as an admission that the Reporting Persons are the beneficial owners of any securities reported in this Form 3. F4: Generally, upon the exercise of any security convertible or exchangeable for any ArQule common stock by the stockholders party to the Support Agreements, such shares of common stock acquired upon exercise thereof shall be subject to the Support Agreements and the Reporting Persons may be deemed to have beneficial ownership of such additional shares of common stock, if any. The Reporting Persons expressly disclaim any beneficial ownership of the securities reported herein, and the Reporting Persons do not have any pecuniary interest (as defined in Rule 16a-1(a)(2) of the Exchange Act) in any of the shares subject to the Support Agreements. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 3 is being filed solely due to the entry by Merck Sharp & Dohme Corp. ("Parent") and Argon Merger Sub, Inc. ("Purchaser") into Support Agreements (each, a "Support Agreement") with certain stockholders of ArQule, Inc. ("ArQule"). The Support Agreements were entered into in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 6, 2019, by and among the Parent, Purchaser and ArQule. For additional information regarding the Support Agreements and the Merger Agreement, see the Schedule 13D filed by the Reporting Person with the Securities and Exchange Commission on December 16, 2019 (the "Schedule 13D").
F2: Purchaser is a direct wholly-owned subsidiary of Parent and Parent is a direct wholly-owned subsidiary of Merck & Co., Inc. ("Merck", and together with Parent, the "Reporting Persons"). As a result of certain provisions contained in the Support Agreements, the Reporting Persons may be deemed to have beneficial ownership of the shares of common stock covered by the Support Agreements and beneficially owned by the stockholders party thereto (an aggregate of 17,481,903 shares, which represent approximately 12.6% of ArQule's total outstanding shares as of the close of business on December 5, 2019, based on the representations made by ArQule in the Merger Agreement) for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")).
F3: Each of the Reporting Persons declare that the filing of this Form 3 shall not be construed as an admission that the Reporting Persons are the beneficial owners of any securities reported in this Form 3.
F4: Generally, upon the exercise of any security convertible or exchangeable for any ArQule common stock by the stockholders party to the Support Agreements, such shares of common stock acquired upon exercise thereof shall be subject to the Support Agreements and the Reporting Persons may be deemed to have beneficial ownership of such additional shares of common stock, if any. The Reporting Persons expressly disclaim any beneficial ownership of the securities reported herein, and the Reporting Persons do not have any pecuniary interest (as defined in Rule 16a-1(a)(2) of the Exchange Act) in any of the shares subject to the Support Agreements.
BeOne Medicines Ltd.
Report date February 08, 2016 · Filed February 10, 2016
Jointly reported with Merck Sharp & Dohme Corp., Merck Sharp & Dohme Research GmbH
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectVia wholly owned subsidiary, MSDRG | 18,518,519 |
Reported balance
After 2016-02-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2016-02-08 · Conversion · Acquired 18,518,519 · Balance 18,518,519 F1: The Series A Preferred Shares (the "Series A Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date. F2: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. |
| Ordinary SharesSEC Table I · non-derivative | IndirectVia wholly owned subsidiary, MSDRG | 5,128,205 |
Reported balance
After 2016-02-08 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2016-02-08 · Conversion · Acquired 5,128,205 · Balance 5,128,205 F3: The Series A-2 Preferred Shares (the "Series A-2 Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A-2 Shares did not have an expiration date. F2: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. |
| Ordinary SharesSEC Table I · non-derivative | IndirectVia wholly owned subsidiary, MSDRG | 7,942,314 |
Reported balance
After 2016-02-08 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2016-02-08 · Other · Acquired 7,942,314 · Balance 7,942,314 F4: The 7,942,314 Ordinary Shares were issued to MSDRG in exchange for the cancellation of MSDRG's promissory note plus accrued and unpaid interest thereon (together, $14,693,281)(the "Note Exchange Amount") upon the closing of the initial public offering of the Issuer. The number of shares issued was determined by dividing the Note Exchange Amount by the initial public offering share price of $1.85. F2: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. |
| Series A Preferred SharesSEC Table II · derivative / convertible security | IndirectVia wholly owned subsidiary, MSDRG | 0 |
Reported balance
After 2016-02-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-02-08 · Conversion · Disposed 18,518,519 · Balance 0 F1: The Series A Preferred Shares (the "Series A Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date. F2: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. |
| Series A-2 Preferred SharesSEC Table II · derivative / convertible security | IndirectVia wholly owned subsidiary, MSDRG | 0 |
Reported balance
After 2016-02-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-02-08 · Conversion · Disposed 5,128,205 · Balance 0 F2: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. F1: The Series A Preferred Shares (the "Series A Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date. F3: The Series A-2 Preferred Shares (the "Series A-2 Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A-2 Shares did not have an expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series A Preferred Shares (the "Series A Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date.
F2: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.
F3: The Series A-2 Preferred Shares (the "Series A-2 Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A-2 Shares did not have an expiration date.
F4: The 7,942,314 Ordinary Shares were issued to MSDRG in exchange for the cancellation of MSDRG's promissory note plus accrued and unpaid interest thereon (together, $14,693,281)(the "Note Exchange Amount") upon the closing of the initial public offering of the Issuer. The number of shares issued was determined by dividing the Note Exchange Amount by the initial public offering share price of $1.85.
NGM BIOPHARMACEUTICALS INC
Report date April 08, 2019 · Filed April 09, 2019
Jointly reported with Merck Sharp & Dohme Corp.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 12,955,016 |
Last balance in matching sequence
After 2019-04-08 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2019-04-08 · Conversion · Acquired 8,833,333 · Balance 8,833,333 F1: Each share of Series E Convertible Preferred Stock automatically converted into one-half (0.5) of a share of common stock immediately prior to the closing of the Issuer's initial public offering, and has no expiration date. F2: These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities. Row 2 · 2019-04-08 · Purchase · Acquired 4,121,683 · Balance 12,955,016 F2: These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities. |
| Series E Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2019-04-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-04-08 · Conversion · Disposed 17,666,666 · Balance 0 F1: Each share of Series E Convertible Preferred Stock automatically converted into one-half (0.5) of a share of common stock immediately prior to the closing of the Issuer's initial public offering, and has no expiration date. F2: These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series E Convertible Preferred Stock automatically converted into one-half (0.5) of a share of common stock immediately prior to the closing of the Issuer's initial public offering, and has no expiration date.
F2: These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities.
Pandion Therapeutics, Inc.
Report date February 24, 2021 · Filed March 04, 2021
Jointly reported with MERCK SHARP & DOHME LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001SEC Table I · non-derivative | IndirectSee Footnotes | 0 |
Reported balance
Holding disclosure · report date 2021-02-24 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 F1: This Form 3 is being filed solely due to the entry by Merck Sharp & Dohme Corp. ("Parent") and Panama Merger Sub, Inc. ("Purchaser") into Tender and Support Agreements (each, a "Support Agreement") with certain stockholders of Pandion Therapeutics, Inc. (the "Company"). The Support Agreements were entered into in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 24, 2021, by and among the Parent, Purchaser and the Company. For additional information regarding the Support Agreements and the Merger Agreement, see the Schedule 13D filed by the Reporting Person with the Securities and Exchange Commission on March 4, 2021 (the "Schedule 13D"). F2: Purchaser is a direct wholly-owned subsidiary of Parent and Parent is a direct wholly-owned subsidiary of Merck & Co., Inc. ("Merck", and together with Parent, the "Reporting Persons"). As a result of certain provisions contained in the Support Agreements, the Reporting Persons may be deemed to have beneficial ownership of the shares of common stock covered by the Support Agreements and beneficially owned by the stockholders party thereto (an aggregate of 11,776,706 shares, which represent approximately 39.99% of the Company's total outstanding shares as of the close of business on February 24, 2021, based on the representations made by the Company in the Merger Agreement) for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")). F3: Each of the Reporting Persons declare that the filing of this Form 3 shall not be construed as an admission that the Reporting Persons are the beneficial owners of any securities reported in this Form 3. F4: Generally, upon the exercise of any security convertible or exchangeable for any common stock of the Company by the stockholders party to the Support Agreements, such shares of common stock acquired upon exercise thereof shall be subject to the Support Agreements and the Reporting Persons may be deemed to have beneficial ownership of such additional shares of common stock, if any. The Reporting Persons expressly disclaim any beneficial ownership of the securities reported herein, and the Reporting Persons do not have any pecuniary interest (as defined in Rule 16a-1(a)(2) of the Exchange Act) in any of the shares subject to the Support Agreements. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security | IndirectSee Footnotes | Not disclosed |
Reported balance
Holding disclosure · report date 2021-02-24 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: This Form 3 is being filed solely due to the entry by Merck Sharp & Dohme Corp. ("Parent") and Panama Merger Sub, Inc. ("Purchaser") into Tender and Support Agreements (each, a "Support Agreement") with certain stockholders of Pandion Therapeutics, Inc. (the "Company"). The Support Agreements were entered into in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 24, 2021, by and among the Parent, Purchaser and the Company. For additional information regarding the Support Agreements and the Merger Agreement, see the Schedule 13D filed by the Reporting Person with the Securities and Exchange Commission on March 4, 2021 (the "Schedule 13D"). F2: Purchaser is a direct wholly-owned subsidiary of Parent and Parent is a direct wholly-owned subsidiary of Merck & Co., Inc. ("Merck", and together with Parent, the "Reporting Persons"). As a result of certain provisions contained in the Support Agreements, the Reporting Persons may be deemed to have beneficial ownership of the shares of common stock covered by the Support Agreements and beneficially owned by the stockholders party thereto (an aggregate of 11,776,706 shares, which represent approximately 39.99% of the Company's total outstanding shares as of the close of business on February 24, 2021, based on the representations made by the Company in the Merger Agreement) for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")). F3: Each of the Reporting Persons declare that the filing of this Form 3 shall not be construed as an admission that the Reporting Persons are the beneficial owners of any securities reported in this Form 3. F4: Generally, upon the exercise of any security convertible or exchangeable for any common stock of the Company by the stockholders party to the Support Agreements, such shares of common stock acquired upon exercise thereof shall be subject to the Support Agreements and the Reporting Persons may be deemed to have beneficial ownership of such additional shares of common stock, if any. The Reporting Persons expressly disclaim any beneficial ownership of the securities reported herein, and the Reporting Persons do not have any pecuniary interest (as defined in Rule 16a-1(a)(2) of the Exchange Act) in any of the shares subject to the Support Agreements. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 3 is being filed solely due to the entry by Merck Sharp & Dohme Corp. ("Parent") and Panama Merger Sub, Inc. ("Purchaser") into Tender and Support Agreements (each, a "Support Agreement") with certain stockholders of Pandion Therapeutics, Inc. (the "Company"). The Support Agreements were entered into in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 24, 2021, by and among the Parent, Purchaser and the Company. For additional information regarding the Support Agreements and the Merger Agreement, see the Schedule 13D filed by the Reporting Person with the Securities and Exchange Commission on March 4, 2021 (the "Schedule 13D").
F2: Purchaser is a direct wholly-owned subsidiary of Parent and Parent is a direct wholly-owned subsidiary of Merck & Co., Inc. ("Merck", and together with Parent, the "Reporting Persons"). As a result of certain provisions contained in the Support Agreements, the Reporting Persons may be deemed to have beneficial ownership of the shares of common stock covered by the Support Agreements and beneficially owned by the stockholders party thereto (an aggregate of 11,776,706 shares, which represent approximately 39.99% of the Company's total outstanding shares as of the close of business on February 24, 2021, based on the representations made by the Company in the Merger Agreement) for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")).
F3: Each of the Reporting Persons declare that the filing of this Form 3 shall not be construed as an admission that the Reporting Persons are the beneficial owners of any securities reported in this Form 3.
F4: Generally, upon the exercise of any security convertible or exchangeable for any common stock of the Company by the stockholders party to the Support Agreements, such shares of common stock acquired upon exercise thereof shall be subject to the Support Agreements and the Reporting Persons may be deemed to have beneficial ownership of such additional shares of common stock, if any. The Reporting Persons expressly disclaim any beneficial ownership of the securities reported herein, and the Reporting Persons do not have any pecuniary interest (as defined in Rule 16a-1(a)(2) of the Exchange Act) in any of the shares subject to the Support Agreements.
Personalis, Inc.
Report date December 19, 2024 · Filed December 23, 2024
Jointly reported with MERCK SHARP & DOHME LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par value per shareSEC Table I · non-derivative | IndirectSee footnotes | 14,044,943 |
Reported balance
Holding disclosure · report date 2024-12-19 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 14,044,943 F1: On December 19, 2024, Merck Sharp & Dohme LLC ("MSD") entered into an Investment Agreement with Personalis, Inc. (the "Company"), pursuant to which MSD purchased from the Company 14,044,943 shares of the Company's common stock, par value $0.0001 per share, at a price per share of $3.56. F2: MSD is a direct wholly-owned subsidiary of Merck & Co., Inc. ("Merck", and together with MSD, the "Reporting Persons"). F3: Each of the Reporting Persons declare that the filing of this Form 3 shall not be construed as an admission that the Reporting Persons are the beneficial owners of any securities reported in this Form 3. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 19, 2024, Merck Sharp & Dohme LLC ("MSD") entered into an Investment Agreement with Personalis, Inc. (the "Company"), pursuant to which MSD purchased from the Company 14,044,943 shares of the Company's common stock, par value $0.0001 per share, at a price per share of $3.56.
F2: MSD is a direct wholly-owned subsidiary of Merck & Co., Inc. ("Merck", and together with MSD, the "Reporting Persons").
F3: Each of the Reporting Persons declare that the filing of this Form 3 shall not be construed as an admission that the Reporting Persons are the beneficial owners of any securities reported in this Form 3.
SUTRO BIOPHARMA, INC.
Report date October 01, 2018 · Filed October 02, 2018
Jointly reported with Merck Sharp & Dohme Corp.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,723,509 |
Last balance in matching sequence
After 2018-10-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-10-01 · Conversion · Acquired 2,056,843 · Balance 2,056,843 F1: Each share of Series E redeemable convertible preferred stock (the "Series E Preferred") automatically converted into 0.0275 shares of the Issuer's common stock upon the closing of the Issuer's sale of its common stock in its firm commitment underwritten initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended. The Series E Preferred had no expiration date. F2: These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities. Row 2 · 2018-10-01 · Purchase · Acquired 666,666 · Balance 2,723,509 F2: These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities. |
| Series E Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-10-01 · Conversion · Disposed 74,794,315 · Balance 0 F1: Each share of Series E redeemable convertible preferred stock (the "Series E Preferred") automatically converted into 0.0275 shares of the Issuer's common stock upon the closing of the Issuer's sale of its common stock in its firm commitment underwritten initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended. The Series E Preferred had no expiration date. F2: These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series E redeemable convertible preferred stock (the "Series E Preferred") automatically converted into 0.0275 shares of the Issuer's common stock upon the closing of the Issuer's sale of its common stock in its firm commitment underwritten initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended. The Series E Preferred had no expiration date.
F2: These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities.
Yarrow Bioscience, Inc.
Report date January 24, 2018 · Filed January 25, 2018
Jointly reported with Merck Sharp & Dohme Corp.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,243,168 |
Reported balance
Holding disclosure · report date 2018-01-24 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,243,168 F1: These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CapForce Inc.
Report date December 31, 2017 · Filed February 08, 2018
Jointly reported with Merck Sharp & Dohme Corp., Merck Global Health Innovation Fund, LLC
Section 16 reporting ended · disclosed 2018-02-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $19.50 · Expires 2022-06-28 | IndirectSee footnote | 13,120 |
Reported balance
After 2017-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-28 · Grant · Acquired 13,120 · Balance 13,120 F1: These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018. F2: These securities are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. |
Filing footnotes · ownership attribution and instrument terms
F1: These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018.
F2: These securities are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities.
Harpoon Therapeutics, Inc.
Report date March 11, 2024 · Filed March 11, 2024
Jointly reported with MERCK SHARP & DOHME LLC
Section 16 reporting ended · disclosed 2024-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | IndirectSee Footnote | 1,000 |
Reported balance
After 2024-03-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-03-11 · Purchase · Acquired 21,397,205 · Balance 1,000 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 7, 2024 by and among Merck Sharp & Dohme LLC, a wholly owned subsidiary of Merck & Co. Inc. ("Parent"), Hawaii Merger Sub, Inc., a wholly owned subsidiary of Merck Sharp & Dohme LLC ("Merger Sub"), and Harpoon Therapeutics, Inc. ("Harpoon"), Merger Sub merged with and into Harpoon (the "Merger") on March 11, 2024. Upon completion of the Merger, each share of common stock of Harpoon that was issued and outstanding immediately prior to the effective time of the Merger was cancelled, and each share of common stock of Merger Sub was converted into one share of common stock of the surviving corporation. F2: (Continued from footnote 1) Consequently, upon the consummation of the Merger on March 11, 2024, Parent became the direct beneficial owner of 1,000 shares of common stock of the surviving corporation, representing 100% of the issued and outstanding shares of common stock of the surviving corporation. Merck & Co., Inc. is the indirect beneficial owner of such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of January 7, 2024 by and among Merck Sharp & Dohme LLC, a wholly owned subsidiary of Merck & Co. Inc. ("Parent"), Hawaii Merger Sub, Inc., a wholly owned subsidiary of Merck Sharp & Dohme LLC ("Merger Sub"), and Harpoon Therapeutics, Inc. ("Harpoon"), Merger Sub merged with and into Harpoon (the "Merger") on March 11, 2024. Upon completion of the Merger, each share of common stock of Harpoon that was issued and outstanding immediately prior to the effective time of the Merger was cancelled, and each share of common stock of Merger Sub was converted into one share of common stock of the surviving corporation.
F2: (Continued from footnote 1) Consequently, upon the consummation of the Merger on March 11, 2024, Parent became the direct beneficial owner of 1,000 shares of common stock of the surviving corporation, representing 100% of the issued and outstanding shares of common stock of the surviving corporation. Merck & Co., Inc. is the indirect beneficial owner of such shares.
Organon & Co.
Report date June 02, 2021 · Filed June 04, 2021
Section 16 reporting ended · disclosed 2021-06-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-06-02 transaction · row 1
1 source rowRow 1 · 2021-06-02 · Other · Disposed 253,516,000 · Balance 0 F1: Pursuant to the Separation and Distribution Agreement, dated as of June 2, 2021, Merck & Co., Inc. ("Merck") distributed to the holders of its common stock by means of a pro-rata distribution without consideration an aggregate of 253,516,000 shares of common stock of Organon & Co. (the "Separation"). F2: In connection with the Separation, the 100 shares of common stock of Organon & Co. held by Merck were reclassified into 253,516,000 shares of common stock of Organon & Co. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Separation and Distribution Agreement, dated as of June 2, 2021, Merck & Co., Inc. ("Merck") distributed to the holders of its common stock by means of a pro-rata distribution without consideration an aggregate of 253,516,000 shares of common stock of Organon & Co. (the "Separation").
F2: In connection with the Separation, the 100 shares of common stock of Organon & Co. held by Merck were reclassified into 253,516,000 shares of common stock of Organon & Co.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2024 Filed Mar 11, 2024 19:27 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | PurchaseCommon Stock, par value $0.0001 | 21,397,205 | $23.00 | $492,135,715.00 |
DisclosureSEC source: 0000950170-24-029165 · ownership.xml · nonDerivative · entry 1 Merck & Co., Inc. · CIK 0000310158 · 10% owner MERCK SHARP & DOHME LLC · CIK 0000064978 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,000 F1 · shares: Pursuant to the Agreement and Plan of Merger, dated as of January 7, 2024 by and among Merck Sharp & Dohme LLC, a wholly owned subsidiary of Merck & Co. Inc. ("Parent"), Hawaii Merger Sub, Inc., a wholly owned subsidiary of Merck Sharp & Dohme LLC ("Merger Sub"), and Harpoon Therapeutics, Inc. ("Harpoon"), Merger Sub merged with and into Harpoon (the "Merger") on March 11, 2024. Upon completion of the Merger, each share of common stock of Harpoon that was issued and outstanding immediately prior to the effective time of the Merger was cancelled, and each share of common stock of Merger Sub was converted into one share of common stock of the surviving corporation. F2 · shares: (Continued from footnote 1) Consequently, upon the consummation of the Merger on March 11, 2024, Parent became the direct beneficial owner of 1,000 shares of common stock of the surviving corporation, representing 100% of the issued and outstanding shares of common stock of the surviving corporation. Merck & Co., Inc. is the indirect beneficial owner of such shares. F1 · balance_after: Pursuant to the Agreement and Plan of Merger, dated as of January 7, 2024 by and among Merck Sharp & Dohme LLC, a wholly owned subsidiary of Merck & Co. Inc. ("Parent"), Hawaii Merger Sub, Inc., a wholly owned subsidiary of Merck Sharp & Dohme LLC ("Merger Sub"), and Harpoon Therapeutics, Inc. ("Harpoon"), Merger Sub merged with and into Harpoon (the "Merger") on March 11, 2024. Upon completion of the Merger, each share of common stock of Harpoon that was issued and outstanding immediately prior to the effective time of the Merger was cancelled, and each share of common stock of Merger Sub was converted into one share of common stock of the surviving corporation. F2 · balance_after: (Continued from footnote 1) Consequently, upon the consummation of the Merger on March 11, 2024, Parent became the direct beneficial owner of 1,000 shares of common stock of the surviving corporation, representing 100% of the issued and outstanding shares of common stock of the surviving corporation. Merck & Co., Inc. is the indirect beneficial owner of such shares. F1 · ownership.nature: Pursuant to the Agreement and Plan of Merger, dated as of January 7, 2024 by and among Merck Sharp & Dohme LLC, a wholly owned subsidiary of Merck & Co. Inc. ("Parent"), Hawaii Merger Sub, Inc., a wholly owned subsidiary of Merck Sharp & Dohme LLC ("Merger Sub"), and Harpoon Therapeutics, Inc. ("Harpoon"), Merger Sub merged with and into Harpoon (the "Merger") on March 11, 2024. Upon completion of the Merger, each share of common stock of Harpoon that was issued and outstanding immediately prior to the effective time of the Merger was cancelled, and each share of common stock of Merger Sub was converted into one share of common stock of the surviving corporation. F2 · ownership.nature: (Continued from footnote 1) Consequently, upon the consummation of the Merger on March 11, 2024, Parent became the direct beneficial owner of 1,000 shares of common stock of the surviving corporation, representing 100% of the issued and outstanding shares of common stock of the surviving corporation. Merck & Co., Inc. is the indirect beneficial owner of such shares. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:46 UTC | Organon & Co. ORG · Entity 4115 | OtherCommon Stock | 253,516,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-022060 · doc4.xml · nonDerivative · entry 1 Merck & Co., Inc. · CIK 0000310158 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Separation and Distribution Agreement, dated as of June 2, 2021, Merck & Co., Inc. ("Merck") distributed to the holders of its common stock by means of a pro-rata distribution without consideration an aggregate of 253,516,000 shares of common stock of Organon & Co. (the "Separation"). F2 · shares: In connection with the Separation, the 100 shares of common stock of Organon & Co. held by Merck were reclassified into 253,516,000 shares of common stock of Organon & Co. F1 · price: Pursuant to the Separation and Distribution Agreement, dated as of June 2, 2021, Merck & Co., Inc. ("Merck") distributed to the holders of its common stock by means of a pro-rata distribution without consideration an aggregate of 253,516,000 shares of common stock of Organon & Co. (the "Separation"). Read SEC document |
| April 08, 2019 Filed Apr 9, 2019 22:27 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | ConversionSeries E Convertible Preferred Stock · Derivative | 17,666,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-020514 · a4.xml · derivative · entry 3 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 8,333,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series E Convertible Preferred Stock automatically converted into one-half (0.5) of a share of common stock immediately prior to the closing of the Issuer's initial public offering, and has no expiration date. F1 · derivative.exercise_date: Each share of Series E Convertible Preferred Stock automatically converted into one-half (0.5) of a share of common stock immediately prior to the closing of the Issuer's initial public offering, and has no expiration date. F1 · derivative.expiration_date: Each share of Series E Convertible Preferred Stock automatically converted into one-half (0.5) of a share of common stock immediately prior to the closing of the Issuer's initial public offering, and has no expiration date. F2 · ownership.nature: These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities. Read SEC document |
| April 08, 2019 Filed Apr 9, 2019 22:27 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 4,121,683 | $16.00 | $65,946,928.00 |
DisclosureSEC source: 0001104659-19-020514 · a4.xml · nonDerivative · entry 2 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 12,955,016 F2 · ownership.nature: These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities. Read SEC document |
| April 08, 2019 Filed Apr 9, 2019 22:27 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | ConversionCommon Stock | 8,833,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-020514 · a4.xml · nonDerivative · entry 1 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,833,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series E Convertible Preferred Stock automatically converted into one-half (0.5) of a share of common stock immediately prior to the closing of the Issuer's initial public offering, and has no expiration date. F2 · ownership.nature: These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 18:31 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionSeries E Redeemable Convertible Preferred Stock · Derivative | 74,794,315 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-059933 · a4.xml · derivative · entry 3 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 2,056,843 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series E redeemable convertible preferred stock (the "Series E Preferred") automatically converted into 0.0275 shares of the Issuer's common stock upon the closing of the Issuer's sale of its common stock in its firm commitment underwritten initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended. The Series E Preferred had no expiration date. F1 · derivative.exercise_date: Each share of Series E redeemable convertible preferred stock (the "Series E Preferred") automatically converted into 0.0275 shares of the Issuer's common stock upon the closing of the Issuer's sale of its common stock in its firm commitment underwritten initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended. The Series E Preferred had no expiration date. F1 · derivative.expiration_date: Each share of Series E redeemable convertible preferred stock (the "Series E Preferred") automatically converted into 0.0275 shares of the Issuer's common stock upon the closing of the Issuer's sale of its common stock in its firm commitment underwritten initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended. The Series E Preferred had no expiration date. F2 · ownership.nature: These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 18:31 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | PurchaseCommon Stock | 666,666 | $15.00 | $9,999,990.00 |
DisclosureSEC source: 0001104659-18-059933 · a4.xml · nonDerivative · entry 2 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,723,509 F2 · ownership.nature: These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 18:31 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionCommon Stock | 2,056,843 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-059933 · a4.xml · nonDerivative · entry 1 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,056,843 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series E redeemable convertible preferred stock (the "Series E Preferred") automatically converted into 0.0275 shares of the Issuer's common stock upon the closing of the Issuer's sale of its common stock in its firm commitment underwritten initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended. The Series E Preferred had no expiration date. F2 · ownership.nature: These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities. Read SEC document |
| June 28, 2017 Filed Feb 8, 2018 21:05 UTC | CapForce Inc. OPGN · Entity 9776 | GrantWarrant to Purchase Common Stock · Derivative | 13,120 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0000899243-18-003274 · doc5.xml · derivative · entry 1 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Merck Global Health Innovation Fund, LLC · CIK 0001547132 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 13,120 Underlying: Common Stock · 13,120 shares Expires 2022-06-28 F1 · derivative.exercise_price: These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018. F1 · shares: These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018. F1 · derivative.underlying_shares: These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018. F1 · balance_after: These amounts reflect the Issuer's recently announced and effectuated a 1 for 25 reverse stock split on January 17, 2018. F2 · ownership.nature: These securities are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. Read SEC document |
| June 27, 2016 Filed Jun 29, 2016 20:05 UTC | CapForce Inc. OPGN · Entity 9776 | PurchaseWarrants · Derivative | 2,050,821 | Not disclosed Strike: $1.31 | Not disclosed |
DisclosureSEC source: 0000899243-16-023850 · doc4.xml · derivative · entry 2 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Merck Global Health Innovation Fund, LLC · CIK 0001547132 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,950,821 Underlying: Common Stock · 2,050,821 shares Expires 2021-06-27 F1 · price: The reported securities were included within units ("Units") with each Unit consisting of one share of the Company's common stock, par value $0.01 per share (the "Common Stock") and (ii) a warrant to acquire 0.75 of one share of Common Stock for a purchase price of $1.14375 per Unit. F2 · ownership.nature: These securities are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. Read SEC document |
| June 27, 2016 Filed Jun 29, 2016 20:05 UTC | CapForce Inc. OPGN · Entity 9776 | GrantCommon Stock | 2,734,427 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-023850 · doc4.xml · nonDerivative · entry 1 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Merck Global Health Innovation Fund, LLC · CIK 0001547132 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,413,449 F1 · price: The reported securities were included within units ("Units") with each Unit consisting of one share of the Company's common stock, par value $0.01 per share (the "Common Stock") and (ii) a warrant to acquire 0.75 of one share of Common Stock for a purchase price of $1.14375 per Unit. F2 · ownership.nature: These securities are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. Read SEC document |
| May 19, 2016 Filed May 24, 2016 20:41 UTC | CapForce Inc. OPGN · Entity 9776 | PurchaseCommon Stock and Warrants (Obligation to buy Units) · Derivative | 2,734,427 | Not disclosed Strike: $1.14 | Not disclosed |
DisclosureSEC source: 0000899243-16-020819 · doc4.xml · derivative · entry 3 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Merck Global Health Innovation Fund, LLC · CIK 0001547132 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,685,248 Underlying: Common Stock · 4,785,248 shares Expires not disclosed F3 · price: Represents future obligation of MGHIF to purchase additional Units for a purchase price of $1.14375 per Unit within 60 days and subject to stockholder consent and notice to stockholders of same (including the filing of Schedule 14C and the twenty day waiting period), pursuant to the Amended and Restated Securities Purchase Agreement entered into on May 18, 2016. F3 · derivative.exercise_date: Represents future obligation of MGHIF to purchase additional Units for a purchase price of $1.14375 per Unit within 60 days and subject to stockholder consent and notice to stockholders of same (including the filing of Schedule 14C and the twenty day waiting period), pursuant to the Amended and Restated Securities Purchase Agreement entered into on May 18, 2016. F3 · derivative.expiration_date: Represents future obligation of MGHIF to purchase additional Units for a purchase price of $1.14375 per Unit within 60 days and subject to stockholder consent and notice to stockholders of same (including the filing of Schedule 14C and the twenty day waiting period), pursuant to the Amended and Restated Securities Purchase Agreement entered into on May 18, 2016. F2 · ownership.nature: These shares are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. Read SEC document |
| May 19, 2016 Filed May 24, 2016 20:41 UTC | CapForce Inc. OPGN · Entity 9776 | PurchaseWarrants · Derivative | 900,000 | Not disclosed Strike: $1.31 | Not disclosed |
DisclosureSEC source: 0000899243-16-020819 · doc4.xml · derivative · entry 2 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Merck Global Health Innovation Fund, LLC · CIK 0001547132 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2021-05-19 F1 · price: The reported securities are included within units ("Units") each Unit consisting of one share of the Company's common stock, par value $0.01 per share (the "Common Stock") and (ii) a warrant to acquire 0.75 of one share of Common Stock for a purchase price of $1.14375 per Unit. F2 · ownership.nature: These shares are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. Read SEC document |
| May 19, 2016 Filed May 24, 2016 20:41 UTC | CapForce Inc. OPGN · Entity 9776 | GrantCommon Stock | 1,200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-020819 · doc4.xml · nonDerivative · entry 1 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Merck Global Health Innovation Fund, LLC · CIK 0001547132 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,679,022 F1 · price: The reported securities are included within units ("Units") each Unit consisting of one share of the Company's common stock, par value $0.01 per share (the "Common Stock") and (ii) a warrant to acquire 0.75 of one share of Common Stock for a purchase price of $1.14375 per Unit. F2 · ownership.nature: These shares are owned directly by Merck Global Health Innovation Fund, LLC ("MGHIF"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. Read SEC document |
| February 08, 2016 Filed Feb 10, 2016 21:28 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | ConversionSeries A-2 Preferred Shares · Derivative | 5,128,205 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001635698-16-000062 · form4.xml · derivative · entry 5 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Merck Sharp & Dohme Research GmbH · CIK 0001665244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Via wholly owned subsidiary, MSDRG Disclosed balance after: 0 Underlying: Ordinary Shares · 5,128,205 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. F1 · derivative.exercise_price: The Series A Preferred Shares (the "Series A Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date. F1 · price: The Series A Preferred Shares (the "Series A Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date. F3 · derivative.exercise_date: The Series A-2 Preferred Shares (the "Series A-2 Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A-2 Shares did not have an expiration date. F3 · derivative.expiration_date: The Series A-2 Preferred Shares (the "Series A-2 Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A-2 Shares did not have an expiration date. F2 · ownership.direct: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. Read SEC document |
| February 08, 2016 Filed Feb 10, 2016 21:28 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | ConversionSeries A Preferred Shares · Derivative | 18,518,519 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001635698-16-000062 · form4.xml · derivative · entry 4 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Merck Sharp & Dohme Research GmbH · CIK 0001665244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Via wholly owned subsidiary, MSDRG Disclosed balance after: 0 Underlying: Ordinary Shares · 18,518,519 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Shares (the "Series A Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date. F1 · price: The Series A Preferred Shares (the "Series A Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date. F1 · derivative.exercise_date: The Series A Preferred Shares (the "Series A Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date. F1 · derivative.expiration_date: The Series A Preferred Shares (the "Series A Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date. F2 · ownership.direct: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. F2 · ownership.nature: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. Read SEC document |
| February 08, 2016 Filed Feb 10, 2016 21:28 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | OtherOrdinary Shares | 7,942,314 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001635698-16-000062 · form4.xml · nonDerivative · entry 3 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Merck Sharp & Dohme Research GmbH · CIK 0001665244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Via wholly owned subsidiary, MSDRG Disclosed balance after: 7,942,314 F4 · kind: The 7,942,314 Ordinary Shares were issued to MSDRG in exchange for the cancellation of MSDRG's promissory note plus accrued and unpaid interest thereon (together, $14,693,281)(the "Note Exchange Amount") upon the closing of the initial public offering of the Issuer. The number of shares issued was determined by dividing the Note Exchange Amount by the initial public offering share price of $1.85. F4 · price: The 7,942,314 Ordinary Shares were issued to MSDRG in exchange for the cancellation of MSDRG's promissory note plus accrued and unpaid interest thereon (together, $14,693,281)(the "Note Exchange Amount") upon the closing of the initial public offering of the Issuer. The number of shares issued was determined by dividing the Note Exchange Amount by the initial public offering share price of $1.85. F2 · ownership.direct: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. F2 · ownership.nature: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. Read SEC document |
| February 08, 2016 Filed Feb 10, 2016 21:28 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | ConversionOrdinary Shares | 5,128,205 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001635698-16-000062 · form4.xml · nonDerivative · entry 2 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Merck Sharp & Dohme Research GmbH · CIK 0001665244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Via wholly owned subsidiary, MSDRG Disclosed balance after: 5,128,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series A-2 Preferred Shares (the "Series A-2 Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A-2 Shares did not have an expiration date. F2 · ownership.direct: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. F2 · ownership.nature: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. Read SEC document |
| February 08, 2016 Filed Feb 10, 2016 21:28 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | ConversionOrdinary Shares | 18,518,519 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001635698-16-000062 · form4.xml · nonDerivative · entry 1 Merck & Co., Inc. · CIK 0000310158 · 10% owner Merck Sharp & Dohme Corp. · CIK 0000942443 · 10% owner Merck Sharp & Dohme Research GmbH · CIK 0001665244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Via wholly owned subsidiary, MSDRG Disclosed balance after: 18,518,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Shares (the "Series A Shares") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date. F2 · ownership.direct: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. F2 · ownership.nature: The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH ("MSDRG"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. ("MSD"), which is a wholly owned subsidiary of Merck & Co., Inc. ("Merck"). MSD and Merck are indirect beneficial owners of the reported securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.